PMC:7299399 / 26833-27152 JSONTXT

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T100","span":{"begin":32,"end":41},"obj":"Disease"},{"id":"T101","span":{"begin":70,"end":78},"obj":"Disease"}],"attributes":[{"id":"A100","pred":"mondo_id","subj":"T100","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"},{"id":"A101","pred":"mondo_id","subj":"T101","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"}],"text":"onse is central for controlling infection, which also may be true for SARS-CoV-2.88\nSeveral groups and consortia have been screening and characterizing nanomaterials according to their immunomodulatory properties and absence of cytotoxicity.56,57,82−84,86 The development of an adjuvant for clinical use is a lengthy pr"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T266","span":{"begin":307,"end":308},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"}],"text":"onse is central for controlling infection, which also may be true for SARS-CoV-2.88\nSeveral groups and consortia have been screening and characterizing nanomaterials according to their immunomodulatory properties and absence of cytotoxicity.56,57,82−84,86 The development of an adjuvant for clinical use is a lengthy pr"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T200","span":{"begin":278,"end":286},"obj":"Chemical"}],"attributes":[{"id":"A200","pred":"chebi_id","subj":"T200","obj":"http://purl.obolibrary.org/obo/CHEBI_60809"}],"text":"onse is central for controlling infection, which also may be true for SARS-CoV-2.88\nSeveral groups and consortia have been screening and characterizing nanomaterials according to their immunomodulatory properties and absence of cytotoxicity.56,57,82−84,86 The development of an adjuvant for clinical use is a lengthy pr"}

{"project":"LitCovid-PubTator","denotations":[{"id":"401","span":{"begin":70,"end":80},"obj":"Species"},{"id":"407","span":{"begin":32,"end":41},"obj":"Disease"},{"id":"417","span":{"begin":217,"end":240},"obj":"Disease"}],"attributes":[{"id":"A401","pred":"tao:has_database_id","subj":"401","obj":"Tax:2697049"},{"id":"A407","pred":"tao:has_database_id","subj":"407","obj":"MESH:D007239"},{"id":"A417","pred":"tao:has_database_id","subj":"417","obj":"MESH:D064420"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"onse is central for controlling infection, which also may be true for SARS-CoV-2.88\nSeveral groups and consortia have been screening and characterizing nanomaterials according to their immunomodulatory properties and absence of cytotoxicity.56,57,82−84,86 The development of an adjuvant for clinical use is a lengthy pr"}

{"project":"2_test","denotations":[{"id":"32519842-32105090-158510","span":{"begin":81,"end":83},"obj":"32105090"},{"id":"32519842-32373222-158511","span":{"begin":244,"end":246},"obj":"32373222"},{"id":"32519842-29061960-158512","span":{"begin":247,"end":249},"obj":"29061960"},{"id":"32519842-23507086-158513","span":{"begin":250,"end":252},"obj":"23507086"},{"id":"32519842-24885781-158514","span":{"begin":253,"end":255},"obj":"24885781"}],"text":"onse is central for controlling infection, which also may be true for SARS-CoV-2.88\nSeveral groups and consortia have been screening and characterizing nanomaterials according to their immunomodulatory properties and absence of cytotoxicity.56,57,82−84,86 The development of an adjuvant for clinical use is a lengthy pr"}